Results of the European Survey on Anaemia Management 2003 (ESAM 2003): Current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years

Nephrology Dialysis Transplantation

Volumn 20, Issue SUPPL. 3, 2005, Pages

  Jacobs, Claude ^a   Frei, Dieter ^b   Perkins, Alan C ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Ortho Biotech Europe   (Switzerland)

^c Medians   (United Kingdom)

Author keywords

Anaemia; Chronic; Dialysis; Epoetin; Erythropoietin; Iron status; Kidney disease

Indexed keywords

HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; EUROPE; FEMALE; HEALTH SURVEY; HEMODIALYSIS PATIENT; HUMAN; ISRAEL; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; EPOETIN ALFA; ERYTHROPOIETIN, RECOMBINANT; EUROPE; FEMALE; HEALTH SURVEYS; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 19044397278     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh1074     Document Type: Article

References (23)

1. Valderrábano F, Hörl W, Jacobs C, Macdougall IC, eds. European Survey on Anaemia Management (ESAM). Nephrol Dial Transplant 2000; 15 [Suppl 4]: 1-76
2. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999; 14 [Suppl 5]: 1-50
3. Locatelli F, Pisoni RL, Combe C et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19:121-132
4. U.S. Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2004. Available at: www.usrds.org/adr.htm Accessed 17 January 2004
5. ERA-EDTA Registry. ERA-EDTA Registry 2002 Annual Report. Academic Medical Centre, Amsterdam, The Netherlands, May 2004. Available at: www.era-edta-reg.org/files/annualreports/pdf/AnnRep2002.pdf Accessed 13 January 2004
6. Roger SD, Cooper B. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? Nephrology 2004; 9: 223-228
7. Scott SD. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Pharmacotherapy 2002; 22: 160S-165S
8. Nissenson AR, Swan SK, Lindbergh JS et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in dialysis patients. Am J Kidney Dis 2002; 40: 110-118
9. Vanrenterghem Y, Barany P, Mann JF et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHu-EPO in dialysis patients. Kidney Int 2002; 62: 2167-2175
10. Pisoni RL, Bragg-Gresham MS, Young EW et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 94-111
11. Locatelli F, Aljama P, Barany P et al. European Best Practice Guidelines Working Group. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 [Suppl 7]: 1-45
12. NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease. Am J Kidney Dis 2001; 37 [1 Suppl 1]: S182-S238
13. Macdougall IC. Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 1995; 10: 607-614
14. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif 2004; 22: 112-123
15. Richardson D. Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant 2002; 17 [Suppl 1]: 53-59
16. Besarab A, Amin N, Ahsen, M et al. Optimization of epoetin alfa therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-538
17. Hörl WH, Jacobs C, Macdougall IC et al. European best practice guidelines 14-16: inadequate response to epoetin. Nephrol Dial Transplant 2000; 15 [Suppl 4]: 43-50
18. Nitta K, Akiba T, Takei T et al. Inflammation and resistance to erythropoietin in hemodialysis patients. Acta Haematol 2002; 108: 168-170
19. Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002; 17 [Suppl 11]: 39-43
20. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42: 761-773
21. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association (Part 1). Section II. Hemodialysis adequacy. Nephrol Dial Transplant 2002; 17 [Suppl 7]: 16-31
22. Hemodialysis Adequacy Work Group. NKF-DQQI clinical practice guidelines for haemodialysis adequacy, 2000 update. Am J Kidney Dis 2001; 37: S15-S55
23. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoetin in patients with end-stage renal disease. N Engl J Med 1996; 334: 420-425